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Significance for public health 
This study highlights the public health challenge in early screening for colorectal 
cancer (CRC). The prevalence of never screened for faecal occult blood test is 
relatively high. This review dissects the issue and further discuss on the predictors, 






Colorectal cancer (CRC) is a major public health threat. Therefore, CRC screening 
uptake has been a focus with the established precancerous lesion and the strong 
association of early detection with staging and survival of the disease. However, 
CRC screening is relatively low in many countries. This article briefly discussed the 
current situation of CRC, recommendations, and current uptake of CRC screening in 
various countries. Besides that, this article also highlights the potential factors that 
help to predict the CRC screening uptake worldwide. Identification of those factors 
could guide policymakers to develop an effective strategy to improve the CRC 
screening uptake and ultimately improve the health outcome of the population.  
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Introduction  
Colorectal cancer (CRC) is one of the most common cancers in Asia and worldwide 
with an estimation of 10.9% of cancer death among men and 9.5% among women 
[1]. Mortality and morbidity associated with CRC are highly preventable with early 
diagnosis and treatment. Most of the CRC cases appear to develop from benign and 
precancerous polyps in which the incidence and mortality can be reduced by 
performing early screening through the removal of adenomatous polyps and sessile 
serrated polyps [2]. Therefore, it is vital to ensure that the uptake of CRC screening 
reaches the optimal level to reduce the overall CRC incidence and mortality.  
Previous studies reported that various factors influence the public’s decision to avoid 
FOBT screening including sociodemographic and socioeconomic background [3], [4], 
health access factor [5], [6],  preventive  behaviour [7], as well as knowledge  and 
attitude regarding CRC [8]–[12]. This review will briefly discuss the current situation 
of CRC, recommendations for CRC screening, and how various factors could affect 
the uptake of CRC screening. 
 
Global Situation of Colorectal Cancer (CRC) 
In 2018, the International Agency for Research on Cancer (IARC) estimated that 
18.1 million new cases and 9.6 million deaths were related to CRC. CRC was ranked 
as the third most common malignancy worldwide, and the third leading cause of 
cancer detected in men and women. Moreover, CRC is also second-highest cancer 
related to death after lung cancer worldwide [1]. The overall CRC trends of incidence 
and mortality vary between countries with an increasing trend was observed in low- 
and middle-income countries while a more stabilised and decreasing trend was 
observed in high-income countries [13]. The decrease in CRC mortality can be partly 
explained by improved survival of CRC patients through the adoption of best 
practices of cancer management and treatment, early detection efforts, and removal 
of polyps. The introduction of screening methods might initially cause an increase in 
the incidence of CRC. However, in a long term, it has been shown to reduce the 
incidence of CRC by the removal of precancerous polyps via colonoscopy [14]. An 
increase in risk factors such as physical inactivity, cigarette smoking, obesity, and 
low fibre diet have been associated with the increasing trend of CRC prevalence 
especially in low- and middle- income countries [15]. 
 
CRC situation in South East Asia and Malaysia 
The GLOBOCAN project reported that Malaysia has the third-highest overall 
incidence (18.3 per 100,000 population) of CRC in South East Asia (SEA) after 
Singapore (33.7 per 100,000) and Brunei (25.0 per 100,000) [1]. Most SEA countries 
experiencing a rise in CRC due to an increase in lifestyle-related risk factors such as 
unhealthy dietary intake, physical inactivity, and obesity.  
According to Malaysian National Cancer Registry, CRC is the second most common 
cancer (13.5% from all type of cancer) after breast cancer (19.0%) among the 
Malaysian population. It was reported that a total of 15,515 CRC cases were 
registered from 2012 to 2016. In regard to gender, majority of CRC cases were 
reported among males (56.1%) compared to females (43.9%). The lifetime risk of 
CRC among males was 1 in 55 (cumulative risk 1.8) while female reported a ratio of 
1 in 77 (cumulative risk 1.3). CRC was also observed to be the most common cancer 
among males (ASR 14.8) and the second most common among females (ASR 11.1) 
after breast cancer. The lifetime risk among Chinese males was the highest (1 in 43) 
followed by Malay males (1 in 65), and Indian males (1 in 70). A similar trend was 
also observed in females whereby the lifetime risk was highest among Chinese (1 in 
57) followed by Malay (1 in 89) and Indian (1 in 95). According to a report, CRC 
incidence increased with age and peaked at the age of 70 and above for both sexes 
[16].  
Staging of CRC at the time of diagnosis for males was 7.4% at stage I, 20.2% at 
stage II, 32.8% at stage III, and 39.6% at stage IV. Meanwhile, in females, the 
staging at the time of diagnosis was only 6.6% at stage I, 20.3% at stage II, 32.9% at 
stage III, and 40.2% at stage IV. Therefore, at the time of diagnosis, there were 
72.4% CRC cases among males and 73.1% CRC cases among females that were 
already at the advanced cancer stage (stage III and IV) [16]–[18].  It was reported 
that in 2015, malignant neoplasm has become one of the top five major cause of 
deaths in the Malaysian government hospital. Most of the CRC cases were detected 
at the late stage in which more than half of CRC patients were detected at stage III 
and IV [17]. Meanwhile, another study showed that the median age for CRC was 62 
years old with a 65.0 per 100 000 incidence rates among the Chinese. In Sabah, 
Malaysia, indigenous populations develop CRC at an early age and present 
themselves at the hospital when the disease is at the advanced stages [19]. 
 
Natural History and Adenoma-Adenomacarcinoma Sequence  
CRC occurs in the large intestine and rectum whereby it develops on the lining of the 
large bowel starting from precancerous lesion. The precancerous lesions that 
commonly progressed into CRC are adenomas or adenomatous polyps. The 
progression of the precursor lesion of adenomatous polyps into CRC is also known 
as adenoma-adenomacarcinoma sequence [20]. The neoplastic changes initially 
begin within the epithelium of the bowel lining, which is called intraepithelial 
neoplasia. This will then progress into cancer with invasion across the basement 
membrane [21]. The progression of CRC via adenoma-adenomacarcinoma 
sequence has also been reported to be via alternative routes of serrated neoplasia 
pathway. Statistic showed that more than 15% of CRC originated from the serrated 
neoplasia pathway [22]. The potential of cancer development from the precancerous 
lesion can also be explained by the size of adenoma with 1% in small polyps (size 
less than 1cm), 10% in adenomas (size more than 1 cm and less than 2cm), and 
50% in adenomas (size larger than 2cm). A study among Malaysian patients who 
underwent colonoscopy in the government hospital revealed that 58% of polyps 
morphology was sessile with 5-9mm size and 19.1% adenoma detection rate [23]. 
 
 
Screening and CRC Precancerous lesion 
CRC has become the focus of screening due to the established precancerous lesion 
and the strong association of early detection with staging and survival of the disease. 
World Health Organization (WHO) has set ten principles for the establishment of 
screening programmes  to detect the disease [24]. It was stipulated that, 
1) The condition sought is an important health problem 
2) There should be accepted treatment in those with recognised disease 
3) Facilities for diagnosis and treatment must be available 
4) There should be a recognisable early stage of the disease 
5) There should be a suitable test or examination 
6) The test is accepted by the population 
7) The natural history of the disease must be adequately understood 
8) There should be an agreed policy to treat on whom to treat as a patient 
regarding treatment 
9) The cost of diagnosis and treatment must be balanced economically with 
possible expenditure on medical care 
10) The case finding must be a continuing process 
 
CRC Screening Recommendations 
An independent group of experts from the United States Preventive Service Task 
Force (USPSTF) has recommended CRC screening among the average risk 
individuals from 50 to 75 years old. The recommended screening tools include 
Guaiac based FOBT Test (gFOBT) or immunochemical FOBT test (iFOBT) 
conducted annually, flexible sigmoidoscopy for every 5 years, 10 years of yearly 
colonoscopy, CT colonography for 5 years every year or combine test of 10 years of 
yearly flexible sigmoidoscopy with annual iFOBT. These screening 
recommendations are shared by other countries such as the United Kingdom [25], 
[26]. However, some countries are against colonoscopy as a primary CRC screening 
tool due to the lack of high-quality evidence, lack of human resources (require 
gastroenterologist to perform the procedure) with long waiting time for the screening, 
greater potential for harm, and higher risk of complications [27]. FOBT is favourable 
in countries with limited colonoscopy resources [28].  Even though single FOBT has 
low sensitivity to detect CRC [29], [30], many western countries considered FOBT as 
the best population-based screening. This is due to its simplicity and high 
acceptance even in countries with the well-developed healthcare system. In a 
retrospective cohort study among iFOBT screening participants, repeated annual 
iFOBT was associated with high sensitivity for CRC detection [31]. In a population-
based cohort study in Japan, there was a decrease in mortality rate at about 72% 
among individuals who are screened using iFOBT compared to unscreened 
subjects. Although the screening method does not significantly reduce the incidence 
of CRC, it was reported that the screening has been associated with the reduction of 
the advanced stage of CRC [32]. In Malaysia, the Ministry of Health has 
recommended selective opportunistic screening among asymptomatic individuals 
from the age of 50 to 75 years old using guaiac-based or immunochemical-based 
faecal occult blood test [33]. 
 
Uptake of CRC Screening 
Participation in screening is one of the key indicators for programme acceptance and 
effectiveness. Due to the availability of screening and treatment option for CRC, 
many countries have been promoting faecal testing in asymptomatic individuals with 
an average risk of CRC development. However, most countries have not achieved 
the desired level of screening uptake. Recommendation by European Commission 
states that the minimum uptake of CRC screening among the average risk group is 
45% with 65% of optimum rate [34]. The American Cancer Society sets a higher goal 
for screening uptake in 2018, which is 80% compared to 75% in 2017 [35]. Despite 
the evidence and presence of specific guidelines, the prevalence of populations that 
have never presented themselves for colorectal screening especially using FOBT 
varies and is relatively high. An intervention study in health clinics in Israel found that 
the prevalence of non-screened for FOBT among the control group (no reminder 
system) was 98.8% [36]. In another intervention study in Canada reported that the 
non-responder to a mail invitation to perform FOBT at the nearest healthcare facility 
was as high as 90.4% [37]. Similar findings were also observed in the United States 
with a 90.1% prevalence of non-compliance to current FOBT screening [5]. 
Canadian health survey showed 76.5% prevalence of respondents who have never 
had any history of colorectal cancer screening [38].  
Meanwhile, in Asia, several countries have recorded variation in CRC screening 
uptake. In Japan, the screening program was in place since 1992 with a participation 
rate of 41.4% in men and 34.5% in women using the Faecal Immunochemical Test 
(FIT) [39]. In South Korea, the CRC screening program using FIT that was 
implemented in 2004 showed a 10.5% increase participation in 2004 to 21.1% in 
2008 and to 25% in 2012 [40]. In Thailand, a pilot program that was implemented in 
2011 showed 37.1% non-participation for FIT [41]. In Taiwan, the defaulters in the 
pilot FIT program were found to be high at 78.6% [42]. 
However, study on the acceptance of CRC screening in Malaysia is limited. A recent 
study performed in Sabah, Malaysia recorded a prevalence of 85.8% population that 
has never been screened by FOBT [43]. Another study among average risk 
individuals in West Malaysia found that there were only 13 respondents or 0.7% (out 
of 1905 respondents) that have been screened for CRC [44]. In a multicentre study 
in the Asia Pacific region, Malaysia recorded among the highest prevalence with 
poor participation of CRC screening (97%) compared to another country in the same 
region such as the Philippines (31%), Japan (62%), and Brunei (86.3%) [45]. The 
issue with screening may benefit from smart healthcare delivery to improve access 
via digital health integration. Screening and referral of cases for further intervention 
can be done earlier [46].  
 
Potential Predictors of CRC Screening Uptake 
Sociodemographic Factors  
There were several studies that have addressed the association of age with CRC 
screening uptake. In a study in England, it was found that older respondents have a 
significantly higher screening uptake compared to the younger age group (60-64: 
62.6% vs 65-70:74.3%, p<0.001) [47]. This finding is consistent with a study in the 
United States that found participants within the age group of 65 to 75 years old has 
2.49 higher odds at receiving CRC screening compared to those of 50 to 64 years 
old [3]. This is in contrast to a longitudinal cohort study in the US whereby the 
likelihood of being up to date to screening practices was lower in the older age group 
(>76 years old) compared to the younger age group (p<0.001). A lower screening 
uptake among the older age group could be explained by the comorbidity influences 
in relation to older age [48]. This contrasts with another report whereby the older age 
group have higher CRC screening uptake, especially in the United States. This is 
due to a special programme implemented by the US known as National Health 
Insurance Programme or Medicare that covers health-related expenses including 
cancer screening for US citizens age 65 years old and above [3].  
Several studies have shown gender inequality in CRC screening uptake. A study in 
the US showed that the utilisation of FOBT was common among women compared 
to men (OR=1.8, 95% CI: 1.6-2.0 [5]. This is consistent with a pilot study in the 
United Kingdom on FIT acceptability that showed men have lower acceptance on 
both guaiac-based FOBT and FIT compared to women [49]. Another study also 
reported a similar finding whereby women has significantly higher screening uptake 
using FIT compared to men (women 50.2% versus men 54.6%, p < 0.001) in a 
population-based CRC screening program in Barcelona [50]. This is further 
supported by a meta-analysis study, which stated that male uptake was significantly 
lower than female uptake for FOBT test (FIT) (OR 0.84; 95% confidence interval 
(CI), 0.75 – 0.95; p < 0.05) [51]. Although the acceptance of screening is low among 
male, the introduction of FIT instead of guaiac-based FOBT testing (gFOBT) has 
significantly increase CRC screening uptake with absolute differences of 8.1% 
(gFOBT 56.4% versus FIT 64.5%, OR 1.41, 95% CI 1.36-1.45) compared to women 
with absolute differences of 6.0 % (gFOBT 62.1% versus FIT 68.1%, OR 1.31, 95% 
CI 1.27 to 1.34) [49].  
A consistent ethnicity inequality in CRC screening uptake has been reported in 
previous literature. A population-based survey among respondents living in England 
reported that non-White participants were less likely to respond to screening 
invitation compared to White (41.5% vs 70.5%, p < 0.001) [47]. A cohort study 
following a screening outreach program from 2004 until 2013 found that the 
screening rate among minorities such as Hispanics (33.1 to 78.3%) and Native 
Americans (29.4 to 74.5%) remains low compared to White in both before and after 
the programme (35.2 to 81.1%) [52]. Poor participation of minority ethnicity could be 
explained by low perceived susceptibility to CRC in non-English speaker especially 
among Asian and Hispanics [4]. Moreover, the low CRC screening uptake has 
resulted in an increased risk of late presentation of CRC among Black people (aOR 
1.80, 95% CI 1.02-3.17, p <0.05) and Asian (aOR 1.41, 95% CI 0.97-2.05, p= 0.07) 
[53]. 
Marital status was consistently associated with healthier behaviour and increased 
adherence to cancer screening. This is proved in a large population study conducted 
in the United Kingdom that found single people had lower CRC screening uptake 
compared to those who were married (55.7% vs 71.7%, p <0.001) [47]. The findings 
are supported by the 2010 Behavioural Risk Factor Surveillance System Survey 
(BRFSS) analysis among adults in the United States whereby individuals who were 
divorced, separated, never married or widowed have lower odds to adhere to the 
CRC screening guidelines compared to married couples [54]. Another analysis of the 
BRFSS survey found that marital status is an independent predictor of cancer 
screening including CRC (OR 1.63, 95% CI: 1.51-1.77) [55]. The findings are 
consistent with another study among Korean American in which married individuals 
are more likely to have sigmoidoscopy compared to unmarried (aOR 4.90, 95% CI: 
1.09, 21.9, p <0.001). One of the mechanisms that explained the association of 
marital status with health behaviour is social control, which refers to regulatory 
attempts by others and feeling of responsibility or obligation towards others that 
facilitate the healthy behaviour [56]. 
 
Education Level 
Education attainment has consistently associated with CRC screening uptake. 
Individuals with lower education level have lower screening participation compared 
to individuals with higher education level (65.7% vs 74.5%, p <0.001) [57]. A contrary 
was reported in another study that stated education level is not associated with 
adherence to CRC screening after adjusted to other individuals covariates [58]. This 
is further supported by another study conducted in Korea that showed education 
level is not significantly associated with compliance to CRC screening 
recommendation [59]. A similar finding was also obtained from a population-based 
study in Hong Kong [12]. This is, however, contrary to a population-based study in 
the United States that found education level at grade 12, college 1-3 years, and 
college 4 years and above are more likely to participate in CRC screening (adjusted 
OR 1.4, 1.7 and 1.9 respectively with p < 0.001) compared to those with lower 
education level [5]. A study in two Danish counties among average risk group for 
CRC screening found that higher education level was more likely to underwent 
FOBT screening (adjusted OR 1.38 (CI 95% 1.33 – 1.43, p < 0.0001) [60]. 
 
Household Income 
There are several studies addressing the association between household income 
and CRC screening participation. A nationwide cross-sectional survey in Korea 
found that lower household income is significantly related to non-compliance to CRC 
screening (p < 0.001) [59]. The findings are consistent with a study in the United 
States that reported high household income is one of the significant predictors of 
current CRC screening (OR 1.9, p <0.001) [5]. A large population study in Denmark 
also reported that individuals at first income quartile (annual household income of 
less than US Dollars 28860.50) has higher odds of non-participation in screening 
recommendation using FOBT compared to individuals with fourth income quartile 
(OR 2.8, CI 95% 2.71 – 2.90) [61]. The data are further supported by a study in 2 
Danish counties whereby participation in FOBT screening is higher in high-income 
level (OR 1.94, CI 95% 1.87 – 2.01) [60]. 
 
Employment Status  
Several studies have established the relationship between employment status with 
the acceptance of CRC screening recommendation. Participants who were not in the 
labour force had more than two times higher odds to receive CRC screening (aOR 
2.32, CI 95% 1.37 – 3.94) [3]. This is similar to a study that showed people who are 
retired or out of work are more likely to have current CRC screening compared to 
people who are employed (adjusted OR 1.2, p <0.001) [5]. Not in the labour force is 
defined as people who are currently unemployed and not seeking employment. 
Compared to people who are not in the labour force, employed individuals may be 
hindered from seeking health care including screening for cancer due to lack of sick 
leaves, the burden of taking days off work, and fear of negative consequences due 
to job insecurity [62].  
 
Interval Visits to Doctor for Routine Check-up 
Several studies have been conducted examining the relationship between routine 
doctor visits with the uptake of CRC screening. In a study in the United States, 
patients who visited a doctor for routine check-up were more likely to receive up to 
date CRC screening in both colonoscopy or sigmoidoscopy (aOR = 2.6, p < 0.001) 
and FOBT test (aOR = 6.2, p < 0.001) compared to those who have not reported any 
routine check-up to a doctor for more than a year [5]. The findings are supported by 
a study among Korean American people at the age of 65 years old and older. This 
population have a more routine check-up of FOBT compared to those who did not 
have routine check-up (aOR 2.61, 95% CI 1.16, 5.9) [63]. Individuals who did not 
have a routine check-up with a doctor are unlikely to undergo cancer screening as 
they are lacking in the opportunity to be screened, advised by doctors, and the 
opportunity to screening tools distributed in the clinic. 
 
Comorbidities  
Study regarding comorbidities and CRC uptake has been cited in several studies. A 
population-based study in Barcelona founds that individuals with three and more 
dominant chronic diseases were associated with low participation in the FOBT test 
(IRR 0.76, 95% CI 0.65, 0.89, p < 0.001) [50]. In another study among eligible 
screening adults found that individuals with type II diabetes were less likely to 
undergo screening using the FOBT test (aOR 0.703, 95% CI 0.557-0.887, p< 0.001) 
[64]. These show the role of multiple comorbidities as a barrier of CRC screening 
due to competing interest of healthcare provider to treat critical issue than 
recommending CRC screening.  
 
Distance from Clinic to House 
The distance from the house to the nearest health facilities and its association with 
health has been cited in a few studies [6], [65], [66]. A study to identify the predictors 
of screening for cognitive impairment founds that the distance from the respondent’s 
residential area is one of the significant predictors of screening participation. The 
distance of 2-2.99km (aOR 0.62, 95% CI: 0.67-0.88) and 3km and more (aOR 0.54, 
0.33-0.89) were less likely to participate in screening after adjusting the 
psychological and demographic factors [6]. A systematic review stated that out of 
108 studies, 77% of studies have identified the distance decay association. This 
shows a negative correlation between travel distances to the nearest health facility 
with health outcome. Patients living far from healthcare facilities have been 
associated with negative health outcome such as low survival rate and longer 
hospital stay [66]. 
 
Barriers of CRC Screening Participation 
Several barriers have been identified that prevents people from getting screened for 
CRC including patient’s factor, physician factor, and system factors. In a multicentre 
international study in Asia Pacific Region, a country with a low participation rate of 
CRC screening had low knowledge of CRC symptoms, risk factors, test, and lack of 
physician recommendation [45]. This is consistent in an FOBT specific test study 
conducted in Singapore. Most of the respondents (48.9%) identified not having CRC 
symptoms followed by inconvenience (31.1%), no family history of colon cancer 
(28.9%), lack of time (28.9%), and lack of reminders or recommendation (28.9%) are 
the reasons for not using FOBT [67]. Another study in the United States reported that 
74% of the respondents identified fear and bowel preparation are the most important 
barriers to colorectal screening (Jones et al., 2010). Patient’s co-morbidity, previous 
refusal by patients, acute care clinic visits, lack of time, and lack of reminders has 
been identified as the most common physician reported barrier towards CRC 
screening [68]. Another study concluded that the most common barrier for CRC 
screening was lack of physician recommendation and lack of knowledge for the need 
of the test [69].  
 
Knowledge of CRC and Screening 
Knowledge is known to be important to influence the health-seeking behaviour and 
individual’s preference to be screened for health condition including CRC. A study in 
West Malaysia found that less than 1% of respondents had undergo screening and 
most of their respondents have low knowledge score towards CRC and screening 
(only 4.1% of respondents have good knowledge score) [70]. A multicentre study 
among Asia Pacific countries found that countries with low participation rate for CRC 
screening had the least knowledge on symptoms, risk factors, test, and the lowest 
recommendation by a physician [45]. The findings are consistent with another study 
that concluded respondents who are within the screening guideline is associated 
with better knowledge regarding CRC (p = 0.001) [71].  
 
Attitude towards CRC Screening 
Attitude is defined as a psychological tendency to view a subject with a degree of 
favour or disfavour. It is a process of individual subjective evaluation influenced by 
rational assessment, emotional responses, and belief [72]. Several studies have 
shown that attitudes may play an important role in cancer screening practices. A 
study in Geneva, Switzerland to explore the factors contributing to practice and 
attitude towards cancer screening found that the strong predictors of cancer practice 
are attitudes towards screening and towards prevention in general [73]. Another 
study that explores the reasons Netherlands have high CRC screening participation 
(prevalence of screening among the Netherlands are relatively high at 75%) were 
due to trust in the government, perception of the seriousness of cancer, preventive 
health screening, and the importance of one’s health as the important factors of the 
public’s view on CRC screening [11]. A study conducted in West Malaysia founds 
that majority of the participants have a poor attitude towards CRC screening and less 
than 1% of participants reported had undergone CRC screening [70].   
 
Conclusion  
CRC incidence and mortality varied widely between countries. Generally, countries 
with high incidence and mortality of CRC experiencing inadequate uptake of CRC 
screening. There are various predictors that contribute to the inadequate screening 
uptake namely demographic inequality (age, gender, ethnicity, marital status), 
socioeconomic factor (education attainment, employment status, household income), 
frequency of visit to the healthcare provider, distance from health services, 
comorbidity, individual’s knowledge and attitude toward CRC and its screening. 
Identification of these predictors and barriers for CRC screening is vital to develop an 
effective strategy to improve the screening uptake and ultimately for better health 
outcome of the population.   
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